A detailed history of Silvercrest Asset Management Group LLC transactions in United Therapeutics Corp stock. As of the latest transaction made, Silvercrest Asset Management Group LLC holds 921 shares of UTHR stock, worth $348,257. This represents 0.0% of its overall portfolio holdings.

Number of Shares
921
Previous 1,226 24.88%
Holding current value
$348,257
Previous $390,000 15.38%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$311.04 - $363.55 $94,867 - $110,882
-305 Reduced 24.88%
921 $330,000
Q2 2024

Aug 14, 2024

SELL
$228.26 - $319.04 $279,846 - $391,143
-1,226 Reduced 50.0%
1,226 $390,000
Q2 2024

Aug 14, 2024

BUY
$228.26 - $319.04 $287,151 - $401,352
1,258 Added 105.36%
2,452 $781,000
Q1 2024

May 15, 2024

BUY
$210.76 - $249.51 $2,950 - $3,493
14 Added 1.19%
1,194 $274,000
Q4 2023

Feb 14, 2024

SELL
$214.88 - $256.94 $3,008 - $3,597
-14 Reduced 1.17%
1,180 $259,000
Q3 2023

Nov 14, 2023

BUY
$211.82 - $248.24 $9,108 - $10,674
43 Added 3.74%
1,194 $269,000
Q2 2023

Aug 14, 2023

BUY
$205.19 - $232.99 $236,173 - $268,171
1,151 New
1,151 $254,000
Q4 2022

Feb 14, 2023

SELL
$205.95 - $280.43 $78,466 - $106,843
-381 Reduced 31.41%
832 $231,000
Q3 2022

Nov 14, 2022

SELL
$203.3 - $244.17 $103,276 - $124,038
-508 Reduced 29.52%
1,213 $254,000
Q2 2022

Aug 15, 2022

SELL
$174.81 - $241.14 $70,273 - $96,938
-402 Reduced 18.94%
1,721 $406,000
Q1 2022

May 16, 2022

BUY
$166.16 - $213.96 $19,274 - $24,819
116 Added 5.78%
2,123 $381,000
Q4 2021

Feb 14, 2022

BUY
$184.32 - $216.08 $369,930 - $433,672
2,007 New
2,007 $434,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $17.2B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Silvercrest Asset Management Group LLC Portfolio

Follow Silvercrest Asset Management Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silvercrest Asset Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silvercrest Asset Management Group LLC with notifications on news.